Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma
Theralase Technologies (TLTFF) has announced significant breakthroughs in treating Non-Hodgkin's Lymphoma (NHL) using their lead compound Rutherrin®. In a preclinical study, Rutherrin® demonstrated effective destruction of NHL when combined with Metformin and radiation in an animal model.
The research utilized A20 mouse lymphoma cells in a highly aggressive tumor model. The treatment protocol involved:
- Rutherrin® administered intravenously 3 times per week
- Daily Metformin injections
- Radiation 5 times per week
The most notable results came from the trimodal therapy combining all three treatments, which led to the best overall response, including one case of complete tumor regression with the mouse remaining tumor-free. NHL represents a significant market opportunity, with global market estimates reaching $16.5 billion by 2031. The disease affected approximately 544,000 new cases globally in 2020, resulting in 260,000 deaths.
Theralase Technologies (TLTFF) ha annunciato importanti progressi nel trattamento del Linfoma Non-Hodgkin (NHL) utilizzando il loro composto principale Rutherrin®. In uno studio preclinico, Rutherrin® ha dimostrato un'efficace distruzione del NHL quando combinato con Metformina e radiazioni in un modello animale.
La ricerca ha utilizzato cellule di linfoma A20 in un modello tumorale altamente aggressivo. Il protocollo di trattamento prevedeva:
- Rutherrin® somministrato per via endovenosa 3 volte a settimana
- Iniezioni giornaliere di Metformina
- Radiazioni 5 volte a settimana
I risultati più significativi sono derivati dalla terapia trimodale che combina tutti e tre i trattamenti, la quale ha portato alla migliore risposta complessiva, inclusa un caso di regressione tumorale completa con il topo rimasto privo di tumore. L'NHL rappresenta un'opportunità di mercato significativa, con stime di mercato globali che raggiungono i 16,5 miliardi di dollari entro il 2031. La malattia ha colpito circa 544.000 nuovi casi a livello globale nel 2020, causando 260.000 decessi.
Theralase Technologies (TLTFF) ha anunciado avances significativos en el tratamiento del Linfoma No Hodgkin (NHL) utilizando su compuesto principal Rutherrin®. En un estudio preclínico, Rutherrin® demostró una efectiva destrucción del NHL cuando se combinó con Metformina y radiación en un modelo animal.
La investigación utilizó células de linfoma A20 en un modelo tumoral altamente agresivo. El protocolo de tratamiento incluyó:
- Rutherrin® administrado por vía intravenosa 3 veces por semana
- Inyecciones diarias de Metformina
- Radiación 5 veces por semana
Los resultados más notables provinieron de la terapia trimodal que combina los tres tratamientos, lo que llevó a la mejor respuesta general, incluyendo un caso de regresión tumoral completa con el ratón permaneciendo libre de tumor. El NHL representa una oportunidad de mercado significativa, con estimaciones de mercado global que alcanzan los 16.5 mil millones de dólares para 2031. La enfermedad afectó aproximadamente 544,000 nuevos casos a nivel mundial en 2020, resultando en 260,000 muertes.
Theralase Technologies (TLTFF)는 그들의 주요 화합물 Rutherrin®을 사용하여 비호지킨 림프종(NHL) 치료에서 중요한 breakthroughs를 발표했습니다. 전임상 연구에서 Rutherrin®은 메트포르민 및 방사선과 결합했을 때 NHL을 효과적으로 파괴하는 것을 보여주었습니다.
이 연구는 매우 공격적인 종양 모델에서 A20 마우스 림프종 세포를 사용했습니다. 치료 프로토콜은 다음을 포함했습니다:
- Rutherrin®를 주 3회 정맥 주사
- 매일 메트포르민 주사
- 주 5회 방사선 치료
가장 주목할 만한 결과는 세 가지 치료를 결합한 삼중 요법에서 나왔으며, 이는 최고의 전반적인 반응으로 이어졌고, 마우스가 종양 없이 남아 있는 완전한 종양 퇴축 사례도 포함되었습니다. NHL은 2031년까지 165억 달러에 달하는 글로벌 시장 기회를 나타냅니다. 이 질병은 2020년 전 세계적으로 약 544,000개의 신규 사례에 영향을 미쳐 260,000명이 사망했습니다.
Theralase Technologies (TLTFF) a annoncé des percées significatives dans le traitement du lymphome non hodgkinien (NHL) en utilisant leur composé principal Rutherrin®. Dans une étude préclinique, Rutherrin® a démontré une destruction efficace du NHL lorsqu'il est combiné avec de la métformine et des radiations dans un modèle animal.
La recherche a utilisé des cellules de lymphome A20 dans un modèle tumoral hautement agressif. Le protocole de traitement comprenait :
- Rutherrin® administré par voie intraveineuse 3 fois par semaine
- Injections quotidiennes de métformine
- Radiations 5 fois par semaine
Les résultats les plus notables proviennent de la thérapie trimodale combinant les trois traitements, qui a conduit à la meilleure réponse globale, y compris un cas de régression tumorale complète avec la souris restant sans tumeur. Le NHL représente une opportunité de marché significative, avec des estimations de marché mondiales atteignant 16,5 milliards de dollars d'ici 2031. La maladie a touché environ 544 000 nouveaux cas dans le monde en 2020, entraînant 260 000 décès.
Theralase Technologies (TLTFF) hat bedeutende Fortschritte bei der Behandlung von Non-Hodgkin-Lymphom (NHL) mit ihrem Hauptbestandteil Rutherrin® angekündigt. In einer präklinischen Studie zeigte Rutherrin® eine effektive Zerstörung von NHL, als es mit Metformin und Strahlentherapie in einem Tiermodell kombiniert wurde.
Die Forschung verwendete A20-Maus-Lymphomzellen in einem hochaggressiven Tumormodell. Das Behandlungsprotokoll umfasste:
- Rutherrin® dreimal pro Woche intravenös verabreicht
- Tägliche Metformin-Injektionen
- Strahlentherapie fünfmal pro Woche
Die bemerkenswertesten Ergebnisse stammten aus der trimodalen Therapie, die alle drei Behandlungen kombinierte, was zu der besten Gesamtreaktion führte, einschließlich eines Falls von vollständiger Tumorrückbildung, bei dem die Maus tumorfrei blieb. NHL stellt eine bedeutende Marktchance dar, mit globalen Marktprognosen, die bis 2031 16,5 Milliarden Dollar erreichen. Die Krankheit betraf 2020 weltweit etwa 544.000 neue Fälle, was zu 260.000 Todesfällen führte.
- Complete tumor regression achieved in one case with trimodal therapy
- Significant increase in life expectancy observed
- Rutherrin® showed efficacy even without radiation
- Targeting large market opportunity ($16.5B by 2031)
- Potential new treatment option for aggressive lymphomas
- Only preclinical stage results (animal testing)
- Complete tumor regression achieved in only one case
- Further studies needed to validate effects on other cancerous tumors
Rutherrin(R), when combined with a common diabetic drug and radiation, was able to effectively destroy Non-Hodgkin's Lymphoma in an animal model.
Toronto, Ontario--(Newsfile Corp. - February 25, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that Rutherrin® has demonstrated an ability to destroy Non-Hodgkin's Lymphoma ("NHL") in an animal model, when combined with Metformin (a common diabetes drug) and radiation.
Rutherrin® is the Company's lead compound currently under development for Intra Venous ("IV") administration to treat numerous cancers; including: brain, lung, pancreatic and muscle invasive bladder cancer.
NHL is a cancer that starts in lymphocytes, a type of white blood cell, located in the bone marrow, blood and lymphatic system. Lymphocytes help protect the body against germs and abnormal cells; including, cancer cells.1
NHL ranked as the 5th to 9th most common cancer in most countries globally, with an estimated 544,000 new cancer cases and 260,000 cancer deaths in 2020.2
The global market for NHL is estimated to reach $USD 16.5 billion by 2031.3
In the latest research, mice were inoculated with A20 mouse lymphoma cells subcutaneously ("SQ") on day 0. At day 10, tumours reached 3 to 5 mm in size.
To simulate proposed human treatments, mice were treated for 3 weeks with:
- Rutherrin® IV (3 times per week)
- Metformin intraperitoneally (daily)
- Radiation (5 times per week)
All treatments were stopped after 3 weeks of treatment and tumour volumes were assessed.
The results support the use of Rutherrin®, activated by both Metformin and radiation, in the effective treatment of NHL in a SQ mouse model.
Figure 1: Treatment without Radiation
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/2786/242318_00bf067ea4f9394d_001full.jpg
Figure 2: Treatment with Radiation
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/2786/242318_00bf067ea4f9394d_002full.jpg
Mark Roufaiel, Ph.D., Research Scientist, Theralase® stated, "The A20 lymphoma tumor model is a highly aggressive model, with limited response and survival following radiation therapy alone. Our findings demonstrate that Rutherrin®, even without radiation, improved survival, and notably, the combination of Rutherrin® and Metformin further improved outcomes beyond either treatment alone. While both Rutherrin® and Metformin separately enhanced the effects of radiation on tumour growth delay and survival, the most striking results were observed when all three therapies—Rutherrin®, Metformin and radiation were combined, leading to the best overall response. Remarkably, we observed one case of complete tumour regression, using trimodal therapy, with the mouse remaining tumour-free to date. These findings highlight the potential of trimodal therapy to significantly improve treatment efficacy in aggressive lymphomas and may open up new avenues for cancer therapy."
Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer, Theralase® stated, "In a very well established A20 NHL animal model, Theralase® was able to demonstrate that combinational treatments with Rutherrin® and Metformin, with and without radiation, allowed for significant tumour destruction. There was a significant increase in life expectancy and an even longer-term cancer-free survival period, when animals were treated with trimodal therapy (Rutherrin®, Metformin and radiation). Future studies will investigate this trimodal therapy on a variety of cancerous tumours to validate their effect. The outcomes of this research may help identify novel therapeutic options, changing the way this and other uncurable diseases are treated. It may also help to overcome resistance mechanisms that develop due to the continuous use of the current treatment methods for NHL. These promising results are reinforcing our dedication to bringing innovative treatment options to people with critical unmet needs."
Roger DuMoulin-White, B.Sc., P.Eng, Pro.Dir., President and Chief Executive Officer, Theralase® stated, "The preclinical and clinical data from the Theralase® research and clinical teams is always world-class. I look forward to working with them to translate this research from lab to clinical development for the benefit of all patients who suffer from these life-threatening diseases."
References:
1 What is non-Hodgkin lymphoma? | Canadian Cancer Society. October 2023
2 Epidemiology of Non-Hodgkin Lymphoma: Global Patterns of Incidence, Mortality, and Trends | Blood | American Society of Hematology. November 2022
3 Global Non-Hodgkin Lymphoma Market
About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
Additional information is available at www.theralase.com and www.sedarplus.ca.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements:
This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.
Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.
All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.
For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
For More Information:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
www.theralase.com
Kristina Hachey, CPA
Chief Financial Officer X 224
khachey@theralase.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242318
FAQ
What were the key results of Theralase's (TLTFF) NHL treatment study?
How is Rutherrin® administered in TLTFF's NHL treatment protocol?
What is the market potential for TLTFF's NHL treatment?
How does TLTFF's Rutherrin® treatment compare to radiation therapy alone?
